Koers Arcturus Therapeutics Ltd Nasdaq
Aandelen
IL0011280240
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 147 mln. 137 mln. | Omzet 2025 * | 241 mln. 225 mln. | Marktkapitalisatie | 717 mln. 668 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -68 mln. -63,37 mln. | Nettowinst (verlies) 2025 * | 3 mln. 2,8 mln. | EV/omzet 2024 * | 2,4 x |
Nettoliquiditeiten 2024 * | 364 mln. 339 mln. | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 2,97 x |
K/w-verhouding 2024 * |
-10,2
x | K/w-verhouding 2025 * |
-154
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 91,25% |
Recentste transcriptie over Arcturus Therapeutics Ltd
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Joseph Payne
CEO | Chief Executive Officer | 52 | 01-03-13 |
Andrew Sassine
DFI | Director of Finance/CFO | 59 | 01-09-19 |
Chief Operating Officer | 45 | 01-01-13 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Edward W. Holmes
BRD | Director/Board Member | 83 | 01-09-19 |
James F. Barlow
BRD | Director/Board Member | 65 | 27-05-18 |
Peter Farrell
CHM | Chairman | 81 | 27-05-18 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+1,77% | 42,86 mld. | |
+45,15% | 41,36 mld. | |
+12,24% | 42,74 mld. | |
-8,83% | 27,68 mld. | |
+7,44% | 25,15 mld. | |
-23,01% | 18,63 mld. | |
+30,56% | 12,37 mld. | |
-1,82% | 11,92 mld. | |
+8,35% | 11,21 mld. |